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The behaviour of breast carcinoma can vary considerably.
The extent of spread, both nodal and distant, at the time of
presentation is important for predicting likely behaviour.
However, practices of surgeons vary with regard to sampling
of axillary lymph nodes. With attempts to improve outcome,
there is also increasing pressure to identify markers which
will subdivide node negative, early stage patients into poor or
good risk categories requiring different adjuvant regimes.
This all means that there is a need to maximise the amount
of prognostic information which can be obtained from the
primary tumour. The result has been many.studies of a wide
variety of markers (e.g. c-erbB-2, p53, oestrogen and pro-
gesterone receptors).
One such marker which has been considered in relation to
prognosis is the lectin derived from Helix pomatia. This may
be better known to many as a delicacy with garlic butter
since it is the edible snail. The results obtained are conflicting
in several respects, and some workers clearly feel that its
benefits are with the palate rather than breast cancer. The
Helix pomatia lectin binds to N acetyl galactosamine when it
is in the form of an end-chain, external non-reducing sugar in
complex glycoconjugates (Gallagher, 1984). It has a higher
affinity for a-linked N acetyl galactosamine than for the
P-linked sugar.
The first report of the application of Helix pomatia lectin
to sections of human breast came from Leathem et al. (1983),
in which binding was observed in normal breast epithelium
and in the majority of carcinomas. This was followed by two
short reports from the same group in which a relationship
between Helix pomatia binding and axillary node metastasis
was described (Leathem et al., 1984; 1985). The first study
had shown consistent binding to normal breast, so it was
rather surprising that binding to breast cancers related to a
feature which is the hallmark of malignancy. Unfortunately
the nature of glycoconjugate(s) to which the lectin was bin-
ding does not seem to have been analysed further at that
time, or subsequently.
The publications following these have all concentrated on
the binding of Helix pomatia to breast cancers and whether
or not it relates to node status and relapse free survival and
overall survival. If Helix pomatia binding is to be of value as
a prognostic marker it should fulfil the minimum criteria
proposed by McGuire (1991) with respect to sample size,
patient population bias, method validation, optimisation of
cut-off values and reproducibility. Currently it does not.
Those studies which considered Helix pomatia binding to
be of prognostic value have been those of Fenlon et al.
(1987); Leathem and Brooks (1987); Fukutomi et al., (1989)
and Brooks and Leathem (1991a), with some differences
between them. The first report from Leathem and Brooks
(1987) suggested that Helix pomatia binding was only of
significance in the pre-menopausal group, whereas their
extended series (199la) found no association with age. Also
its prognostic value was due to its relationship to node status
and was not independent. Those studies which have failed to
find Helix pomatia binding to be of significance have been
those of Galea et al. (1991), Taylor et al. (1991) and Guster-
son et al. (1993) which was an extension of the pilot study of
Taylor et al. Noguchi et al. (1993) considered Helix pomatia
staining to be of some use but to be equivalent to various
clinical parameters in predicting nodal metastasis. Thomas et
al. (1993) in this current issue find it to be associated with
node status but not an independent marker of prognosis.
Why all the differences?
Some of the studies which differ with regard to significance
of Helix pomatia binding have similar frequency of detection,
while other studies which agree with regard to significance
have a different frequency, e.g. Galea et al. (1991) describe
81% as staining and Brooks and Leatham (1991a) 79%
whereas Fukutomi et al. (1989) and Noguchi et al. (1993)
have 45% positive. Gusterson et al. (1993) fall in between at
67%. The disparities could be due to differences in patient
population, methods of detection and assessment of what is
'positive'. The higher scores come from a British population,
the intermediate score from a world-wide study and the low
score from Japan, so patient population could be a factor.
Gusterson et al. (1993) found staining on endothelium in
46% of cases, and Fukutomi et al. (1991) observed staining
of red cells in blood group A patients. Although binding to
blood groups A and AB may not be a factor in all cases, it
could be significant in some and could account for
population-based variations.
The next factor to be considered is method of detection:
the use of a simple peroxidase-labelled lectin vs an indirect
method involving application of an antibody to Helix
pomatia and PAP or avidin-biotin immunohistochemical
methods, or application of biotinylated lectin followed by an
avidin-biotin system. These methods are liable to differ sub-
stantially in their sensitivity. Other variations which were
employed initially by some workers included the use of tryp-
sin to expose cryptic sites. Interestingly, removal of terminal
sialic acid by neuraminidase treatment (Fenlon et al., 1987)
prior to lectin binding completely changed the relationship to
node status. Galea et al. (1991) used the simple direct ap-
proach, while Brooks and Leathem (1991a) used an indirect
approach which would be expected to be more sensitive.
Galea et al. accepted that their failure to identify a correla-
tion between node status and prognosis could be due to the
method. Brooks and Leathem (199la) compared direct and
indirect methods and found only weak correlations with the
former. This seems to support the proposal that the
usefulness of Helix pomatia lectin is critically limited by the
sensitivity of the method. However, the recorded frequency
with which binding of Helix pomatia detected by the two
methods was very similar and Gusterson et al. (1993)
appeared to get the same results when they compared both
methods on the same set of cancers. One explanation could
be that the more sensitive detection system might allow
identification of a glycoprotein with a terminal N acetyl
galactosamine, present at lower levels but nonetheless is
critical for the claimed clinical associations. These uncertain-
ties emphasise the need to know much more about the
structure of the glycoproteins detected by Helix pomatia
binding.
Optimisation of cut-off values is another factor important
in the assessment of prognostic markers. Leathem and
Brooks (1987) considered cases with no staining or very weak
staining of occasional cells to be negative. This was extended
to include cases with up to 50% of cells with weak staining
(Brooks & Leathem, 1991a). However, despite all the other
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differences with regard to Helix pomatia binding, all reports
appear to agree that it is easy to subdivide cases into positive
and negative.
Those studies which find a relationship with prognosis
appear to agree that it is not independent of node status (See
Thomas et al., this issue). The principal value of Helix
pomatia binding might therefore be in prediction of lymph
node status. The question arises how good a prediction is
required. Thus 31.6% of carcinomas with staining had no
evidence of metastasis (Brooks & Leathem, 1991a) although
looked at a different way only 10% of those with no staining
had metastasised. It would be difficult to use Helix pomatia
binding to influence the therapy, based on these figures.
The evidence that tumour cell surface oligosaccharides
have a significant role in metastasis comes from studies of
cell lines, predominantly of murine tumours. The degree of
sialylation of subterminal galactose and N-acetylgalac-
tosamine residues shows a good correlation with metastatic
potential (Yogeeswaran & Salk, 1991; Altevogt et al., 1983).
Blockage of protein glycosylation or oligosaccharide process-
ing results in inhibition of experimental metastasis (Hum-
phries et al., 1986). In theory greater knowledge of the
tumour cell surface glycoproteins involved in metastasis
could help in the design of drugs to inhibit their synthesis,
assembly, or presentation.
The use of lectin binding to identify specific glycoproteins
is fraught with problems. Although lectins bind to specific
sugar groups, these can be common to several glycoproteins
within the same cell or tissue. Minor variations in the com-
position of oligosaccharide chains, not necessarily involving
the lectin-specific sugars, can affect binding. This sort of
microheterogeneity is more frequent in carcinomas (Ogata et
al., 1976). Perhaps because of these problems it has not been
possible to assign prognostic significance to the binding of
other lectins in breast carcinoma (Walker, 1990), and it is not
surprising that conflicting results have been generated from
different studies with the Helix pomatia lectin.
It is evident that while Helix pomatia lectin may be an
interesting research tool to examine breast cancer-associated
glycoproteins it could not be used clinically. What is required
is identification and analysis of the putative metastasis-
related glycoprotein, and the subsequent generation of
specific reagents to it.
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